Oxford Instruments enters into Joint Venture with GD Intressenter AB, comprising Omicron Nanotechnology and Scienta Scientific
28 May 2015

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces that it has entered into a Joint Venture with GD Intressenter AB of Sweden (“GDI”) to create the world’s largest player in the highly specialised Ultra High Vacuum Surface Science field.  The JV will comprise Oxford Instruments’ Omicron Nanotechnology GmbH and associated subsidiaries (“Omicron”) and GDI’s Scienta Scientific AB and associated subsidiaries (“Scienta”).

In consideration for new shares in Scienta, Oxford Instruments has transferred all of its shares in the capital of Omicron to Scienta.  Oxford Instruments holds a 47 per cent interest in the share capital of Scienta and GDI holds 53 per cent.

The JV provides excellent opportunities to enhance product development, cut production costs and broaden the product range, while extending market reach and strengthening customer relationships.

The Board of Directors of the JV will include representatives from GDI and Oxford Instruments.  The CEO of the new business will be Mr Johan Åman who is based in Uppsala, Sweden.  Mr Åman has been CEO of Scienta since 2013 and prior to this he held senior commercial and research positions in Mycronic AB. GDI is backed by a leading Nordic Venture Capital Firm, InnovationsKapital, and other financial investors.

In the twelve months to 31st March 2014, Omicron generated revenue of £28.5 million and a loss before tax of £0.6 million.  The gross assets of Omicron at 30th September 2014 were £26.1 million.  In the financial year to 31st December 2014, Scienta generated revenue of SEK279 million (approximately £24.6 million) and a profit before tax of SEK25 million (approximately £2.2 million).  The gross assets of Scienta at 31st December 2014 were SEK146 million (approximately £12.9 million).  Oxford Instruments has provided a term loan of SEK40 million (approximately £3.1 million) to the JV.  The transaction will result in no profit or loss on the carrying value of Omicron for Oxford Instruments.

Commenting on the establishment of the JV, Jonathan Flint, Chief Executive of Oxford Instruments, stated:

“This new venture will create the largest player in the exciting field of Surface Science and UHV engineering.   Customers will benefit from an enhanced product portfolio and improved service, and the synergies generated by merging the two businesses will provide significant efficiencies and cost savings.”

Lars Hagdahl, Chairman of GDI and of the JV, said:

“I am very pleased with the creation of this JV.  Going forward together we are a larger and stronger business that will be good for our customers, partners and employees.”

Jonathan Flint (Chief Executive) and Kevin Boyd (Group Finance Director) will host a conference call for analysts and investors on this announcement at 08:30 am (UK time), today 28 May. To join the call, please use the dial-in numbers below:

Dial: +44 02031394830
PIN: 32701817#

Enquiries

Oxford Instruments plc    
Tel: +44 (0) 1865 393200
Jonathan Flint, Chief Executive
Kevin Boyd, Group Finance Director    

MHP
Tel: +44 (0) 20 3128 8100
Rachel Hirst / Jamie Ricketts

Download Press Release

Oxford Instruments enters into Joint Venture with GD Intressenter AB, comprising Omicron Nanotechnology and Scienta Scientific

PDF 126KB